CONMED Corporation
General ticker "CNMD" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $1.7B (TTM average)
CONMED Corporation does not follow the US Stock Market performance with the rate: -15.0%.
Estimated limits based on current volatility of 2.3%: low 38.65$, high 40.44$
Factors to consider:
- Earnings expected soon, date: 2026-04-29 amc
- Company pays dividends (irregularly): last record date 2025-09-15, amount 0.20$ (Y0.51%)
- Total employees count: 3900 as of 2024
- US accounted for 16.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Pandemic risks, Regulatory and compliance, Cybersecurity threats, Product development and market acceptance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [30.43$, 51.61$]
- 2026-12-31 to 2027-12-31 estimated range: [30.94$, 51.94$]
Financial Metrics affecting the CNMD estimates:
- Negative: with PPE of 8.8 at the end of fiscal year the price was high
- Positive: Operating cash flow per share per price, % of 13.61 > 12.96
- Positive: -4.72 < Operating profit margin, % of 7.46
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 1.98
- Positive: 42.60 < Shareholder equity ratio, % of 44.42 <= 64.25
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -0.42 <= 0
- Negative: Investing cash flow per share per price, % of -1.67 <= -0.65
- Negative: Industry earnings per price (median), % of -2.21 <= 0
Short-term CNMD quotes
Long-term CNMD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,244.74MM | $1,307.02MM | $1,374.72MM |
| Operating Expenses | $1,124.14MM | $1,106.69MM | $1,272.10MM |
| Operating Income | $120.60MM | $200.33MM | $102.62MM |
| Non-Operating Income | $-39.77MM | $-37.30MM | $-31.50MM |
| Interest Expense | $39.77MM | $37.30MM | $31.09MM |
| R&D Expense | $52.60MM | $54.43MM | $55.88MM |
| Income(Loss) | $80.83MM | $163.03MM | $71.12MM |
| Taxes | $16.37MM | $30.61MM | $24.06MM |
| Profit(Loss)* | $64.46MM | $132.42MM | $47.05MM |
| Stockholders Equity | $834.22MM | $962.68MM | $1,033.10MM |
| Inventory | $318.32MM | $346.72MM | $355.54MM |
| Assets | $2,300.02MM | $2,306.25MM | $2,325.75MM |
| Operating Cash Flow | $125.35MM | $166.97MM | $170.69MM |
| Capital expenditure | $19.03MM | $13.08MM | $19.81MM |
| Investing Cash Flow | $-20.03MM | $-13.08MM | $-20.96MM |
| Financing Cash Flow | $-110.43MM | $-151.00MM | $-135.82MM |
| Earnings Per Share** | $2.10 | $4.29 | $1.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.